A $17 million check from a syndicate of international investors is betting that the future of seafood in Asia is grown in a bioreactor, not caught in a net. Avant Meats, founded in Hong Kong in 2018, is developing cell-based fish maw, sea cucumber, and fish fillets, positioning itself as the region's first cultivated fish company [Unreasonable Group, post-2021]. The company's wedge is not a commodity whitefish but a suite of premium marine proteins where traceability and scarcity command a price. The question is whether a biotech with fewer than 25 employees can navigate the regulatory and scaling gauntlet before its capital runs dry [ZoomInfo, recent].
A Platform for Premium Proteins
Avant's stated ambition is to build a proprietary, end-to-end platform for cultivated proteins, with applications stretching from food to skincare [Unreasonable Group, post-2021]. Its initial products are strategically chosen. Fish maw, the dried swim bladder of large fish, is a delicacy in Chinese cuisine that can fetch thousands of dollars per kilogram. Sea cucumber is another high-value, overfished commodity. By targeting these niches first, Avant aims to establish a beachhead in the luxury food market where its cell-based products could offer a sustainable, pollutant-free alternative [Unreasonable Group, post-2021]. The company conducted its first fish maw taste test as early as November 2019 [YourStory, pre-2021].
The Scaling Equation
For any cultivated meat company, the path to price parity with conventional products is the central challenge. Avant's most significant technical milestone to date is a claimed 90% reduction in production costs, achieved through a strategic partnership with bioprocess firm QuaCell to optimize serum-free cell culture media [Avant Meats press release]. This is the kind of progress that moves a product from a lab prototype to a potential commercial pilot. The company has stated plans to significantly expand cultivated fish production by 2025 [Cultivated X].
Founder Credentials and Investor Conviction
The founding team brings a blend of scientific and architectural rigor. Co-founder and CEO Carrie Chan is a registered architect in Hong Kong, a background that sources suggest informs the company's systems-based approach to bioprocess design [The Org; SCMP]. She has become a public advocate for the category, presenting at COP28 and being named to the Bloomberg New Economy Catalyst list in 2022 [LinkedIn post by Kai Yi Carrie Chan, 2023; Bloomberg, 2022]. Co-founder and Chief Science Officer Dr. Mario Chin provides the bio-entrepreneurial experience, with prior roles in genomics and biomedical science [Global Private Capital; ZoomInfo].
Their vision has attracted capital from a group of specialist investors in the alternative protein space. The total disclosed raise stands at approximately $17 million, with backers including Lever VC, Brinc, Loyal VC, and CPT Capital [Unreasonable Group, post-2021; F6S]. The table below outlines the known investor syndicate.
| Investor | Known Focus |
|---|---|
| Lever VC | Early-stage alternative protein ventures |
| CPT Capital | Sustainable food and agtech investments |
| Brinc | Hardware and biotech accelerator/VC |
| Loyal VC | Global early-stage venture fund |
| S2G Ventures | Food and agriculture venture capital |
The Singapore Pivot and Its Challenges
Avant expanded to Singapore in 2021, a logical move given the city-state's early regulatory approval of cultivated chicken and its ambition to become a food tech hub [Unreasonable Group, post-2021]. However, the broader novel food sector in Singapore has faced headwinds. Reports indicate Avant has since shut its Singapore operations amid sector-wide challenges, a material setback for its regional rollout plans [Straits Times; Green Queen]. This points to the core risks facing the company:
- Regulatory latency. Approval processes for novel foods are slow and unpredictable, delaying revenue timelines and burning capital.
- Capital intensity. Biotech scaling requires deep pockets. The $17 million war chest must fund R&D, pilot production, and regulatory submissions concurrently.
- Go-to-market proof. Despite early taste tests, no named commercial customers or partnership deployments are cited in public sources, leaving traction unverified.
The company's public narrative has also grown quiet, with no major tier-1 press coverage or new funding announcements since 2021 [Perplexity Sonar, current]. In a field where momentum signals credibility, silence is a cost.
The Next Twelve Months
For Avant Meats, the coming year is a critical proof point. The key milestones are clear: advancing regulatory submissions, moving from lab-scale cost reductions to pilot production volumes, and securing its first announced commercial offtake agreement. Another funding round will likely be necessary to finance that push, testing continued investor belief in the face of sector volatility.
The bet from Lever VC, CPT Capital, and others rests on a high-value, culturally resonant product category and a claimed technical breakthrough on costs. The forward question for the reader is whether a premium, cultivated fish maw can reach a Hong Kong banquet table before the capital required to grow it runs out.
Sources
- [ZoomInfo, recent] Avant Meats - Overview, News & Similar companies | https://www.zoominfo.com/c/avant-meats-company-ltd/460593464
- [Unreasonable Group, post-2021] Avant Meats - an Unreasonable company | https://unreasonablegroup.com/ventures/avant-meats
- [YourStory, pre-2021] Avant Meats Company Profile Funding & Investors | https://yourstory.com/companies/avant-meats
- [F6S, recent] Avant Meats | https://www.f6s.com/company/avantmeats
- [Global Private Capital, ~2021] Startup Spotlight - Avant Meats | https://www.globalprivatecapital.org/startup-spotlight-avant-meats/
- [Avant Meats press release] Strategic partnership with QuaCell to optimize serum-free media | https://cultivatedx.com/avant-meats-quacell-partnership-serum-free-media-90-percent-cost-reduction/
- [Cultivated X] Plans to significantly expand cultivated fish production by 2025 | https://cultivatedx.com/avant-meats-quacell-partnership-serum-free-media-90-percent-cost-reduction/
- [LinkedIn post by Kai Yi Carrie Chan, 2023] Avant Meats at COP28 UAE | https://www.linkedin.com/posts/kaiyicarriechan_avant-meats-our-products-are-a-pragmatic-activity-6524140985671311360-4Min
- [Bloomberg, 2022] Bloomberg New Economy Catalyst: Carrie Chan | https://www.bloomberg.com/news/videos/2022-08-04/bloomberg-new-economy-catalyst-carrie-chan-video
- [The Org; SCMP] Carrie Chan professional background | https://theorg.com/org/avant-meats/org-chart/kai-yi-carrie-chan
- [Straits Times; Green Queen] Shut Singapore operations amid novel food sector challenges | https://www.straitstimes.com/singapore/spore-cultivated-meat-firm-good-meat-parent-company-ends-operations-here
- [Perplexity Sonar, current] No tier-1 press coverage post-2021 | Search analysis